Study finds too few with hepatitis C start or stick with treatment

November 6, 2013 by Serena Gordon, Healthday Reporter
Study finds too few with hepatitis C start or stick with treatment
Interferon injections don't always work, but new therapies on the way, experts say.

(HealthDay)—A new study suggests that only a quarter of people with hepatitis C are willing to start the standard treatment for the serious viral infection.

When interferon injections—the current standard —work, which only happens about 16 percent of the time, the risk of dying drops by 45 percent, the University of Southern California researchers said. Unfortunately, the drug doesn't always manage to suppress the virus completely and many people can't tolerate its side effects, which include gastrointestinal problems and anemia.

"This study points out the inadequacies of old therapies for hepatitis C," said Dr. Douglas Dieterich, a professor of medicine and liver diseases at the Icahn School of Medicine at Mount Sinai Hospital in New York City.

Hepatitis C is a viral infection that causes inflammation of the liver. It's transmitted from person to person via blood.

Liver specialists said that although this study may be reflective of what's currently going on in hepatitis C treatment, soon there will be a huge shift in the way the disease is treated.

"There's a revolution afoot in the treatment of hepatitis C," Dieterich said. He said new treatments that are taken in pill form should be approved in the coming months, and the newer medications will be far more effective at treating hepatitis C than interferon. He added that the treatment times also will be shorter.

"By the fourth quarter of next year, we'll have at least two new drug cocktails, curing upwards of 90 percent of patients—even those with cirrhosis," he said.

Dr. David Bernstein, chief of the division of hepatology at North Shore University Hospital in Manhasset, N.Y., said the new treatment options are "exciting, but we need to remain somewhat skeptical because many of the studies were done on small groups."

Most people who have hepatitis C don't have any symptoms, and can go years without knowing they have the virus.

"The bulk of people with hepatitis C were born between 1945 and 1965, and more than three-quarters of those infected don't know they have it," said Dr. Paul Gaglio, medical director of the Montefiore Einstein Center for Transplantation, in New York City.

The current study included more than 360,000 U.S. military veterans who'd been diagnosed with hepatitis C. Ninety-seven percent were male, and their average age was 52. More than half were white and almost one-third were black.

Only 24 percent of the veterans chose to receive treatment for their hepatitis C. Of those who received treatment, just 16.4 percent achieved undetectable levels of the virus in their blood. That likely means that many of the study volunteers may have stopped taking the medication before the recommended 48 weeks of treatment was finished, Bernstein said.

The good news was that when the treatment did work, the risk of dying from any cause dropped by 45 percent.

"This study is indicative of standard practice now," Gaglio said. "Patients don't want to take the treatment because there are lots of side effects. But big changes are coming."

Bernstein said three new treatment regimens likely will be approved by the U.S. Food and Drug Administration in December, and another round of approvals likely will occur in late 2014 or early 2015.

All three experts said the message for people with hepatitis C is to go back to their doctor and get re-evaluated. New treatment options will soon be available, and they'll be available for folks with kidney disease and cirrhosis of the liver.

"The treatment world is really changing," Bernstein said.

Gaglio added that if you were born between 1945 and 1965 and you haven't been tested for C, it's important to get tested to ensure that you aren't infected with the virus.

The study was published online Nov. 5 in the journal JAMA Internal Medicine.

Explore further: Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant

More information: Learn more about hepatitis C from the U.S. National Library of Medicine.

Related Stories

Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant

October 31, 2013
New drug therapies offer promise to some hepatitis C sufferers whose transplanted livers are threated by a recurrence of the disease, including some patients who have had no treatment options.

US panel backs Gilead Sciences' hepatitis C drug (Update)

October 23, 2013
U.S. Food and Drug Administration advisers on Friday unanimously voted in favor of a highly anticipated hepatitis C drug from Gilead Sciences that holds promise for millions infected with the liver-destroying virus.

New hepatitis C drug shows potential in phase 2 trials

October 10, 2013
The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological ...

Hepatitis C screening for baby boomers

April 29, 2013
If you were born during 1945-1965, talk to your doctor about getting tested for hepatitis C. The word "hepatitis" means swelling of the liver. Hepatitis is most often caused by a virus. In the United States, the most common ...

FDA advisers unanimously back J&J hepatitis C drug

October 24, 2013
An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from government experts who say the medication should be approved to treat patients infected with the liver-destroying virus.

More drugs show promise in fighting hepatitis C

August 15, 2013
(HealthDay)—An experimental drug duo may cure some cases of the liver disease hepatitis C, without the severe side effects of standard therapy, a new clinical trial suggests.

Recommended for you

Research examines lung cell turnover as risk factor and target for treatment of influenza pneumonia

July 24, 2017
Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia. Infection with ...

Scientists propose novel therapy to lessen risk of obesity-linked disease

July 24, 2017
With obesity related illnesses a global pandemic, researchers propose in the Journal of Clinical Investigation using a blood thinner to target molecular drivers of chronic metabolic inflammation in people eating high-fat ...

Raccoon roundworm—a hidden human parasite?

July 24, 2017
The raccoon that topples your trashcan and pillages your garden may leave more than just a mess. More likely than not, it also contaminates your yard with parasites—most notably, raccoon roundworms (Baylisascaris procyonis).

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.